Bergenbio As

bergenbio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective axl kinase inhibitors to treat multiple aggressive cancers. the company is a world leader in understanding the central role of axl kinase in promoting cancer spread, immune evasion and drug resistance – the cause of approximately 90 percent of cancer deaths. inhibition of axl kinase activity represents a novel approach to addressing a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering an opportunity to create important new therapeutic options for cancer patients.